2010. ISPOR European Congress – Mixed Treatment Comparison of Bevacizumab-Based Therapies Relative to Doublet-Chemotherapy Combinations to Estimate the Relative Efficacy in Progression Free Survival for Treatment of First-Line Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Yi Y, Chouaid C, Vergnenegre A, Bischo HG, Bergman G, Walzer S, Philips Z. Mixed Treatment Comparison of Bevacizumab-Based Therapies Relative to Doublet-Chemotherapy Combinations to Estimate the Relative Efficacy in Progression Free Survival for Treatment of First-Line Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Value Health. 2010 Nov;13(7):A253–A254. Presented at: ISPOR 13th Annual European Congress; November 7, 2010; Prague, Czech Republic.